Xtl Biopharma ADR (XTLB)

$1.43 +0.13 (10.00%)
Market Cap 6.62M
Revenue (ttm) 0.00
Net Income (ttm) -1.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.03
Volume 2,500
Avg Vol 5,260
Day's Range N/A - N/A
Shares Out 5.45M
Stochastic %K 85%
Beta 1.11
Analysts Strong Buy
Price Target $6.00

Latest News on XTLB

XTL Names Mr. Noam Band as its New Chief Executive Officer

Apr 7, 2025, 9:15 AM EDT - 19 days ago

XTL Names Mr. Noam Band as its New Chief Executive Officer

XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 Million

Aug 14, 2024, 9:15 AM EDT - 9 months ago

XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 Million

XTL Entered Definitive Agreement to Acquire The Social Proxy

Jun 5, 2024, 9:15 AM EDT - 11 months ago

XTL Entered Definitive Agreement to Acquire The Social Proxy

XTL To Aquire The Social Proxy

Mar 20, 2024, 10:15 AM EDT - 1 year ago

XTL To Aquire The Social Proxy

XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel

Oct 20, 2023, 4:00 PM EDT - 1 year ago

XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel

XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Oct 20, 2023, 4:00 PM EDT - 1 year ago

XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Dr. Morris C. Laster Files Preliminary Proxy Statement Nominating Two Highly-Qualified Individuals For Election To Board At Scopus BioPharma Inc.'s 2021 Annual Meeting

Sep 20, 2021, 9:05 AM EDT - 3 years ago

Dr. Morris C. Laster Files Preliminary Proxy Statement Nominating Two Highly-Qualified Individuals For Election To Board At Scopus BioPharma Inc.'s 2021 Annual Meeting